Literature DB >> 25469036

Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.

Qing-Hong Du1, Lin Han1, Jun-Jie Jiang1, Ya Xu1, Wei-Hong Li1, Peng-Tao Li1, Xin-Yue Wang1, Xu Jia1.   

Abstract

AIM: To investigate the effects of Glytan on splanchnic hemodynamics and its reduction of portal pressure in portal hypertensive rats.
METHODS: Glytan (Ganluotong in Chinese), is composed of salvianolic acid B and diammonium glycyrrhizinate. Portal hypertension (PHT) was induced in the rats by common bile duct ligation (BDL). Hemodynamic studies were performed using the colored microsphere method. Radioimmunoassay (RIA) was used to determine endothelin (ET)-1 levels in the mesenteric circulation. Western blotting methods were used to investigate the effect of Glytan on ET A receptor (ETAR), ET B receptor (ETBR), endothelial NO synthase (eNOS), G-protein-coupled receptor kinase (GRK)2, and β-arrestin 2 expression in the mesentery. The mRNA of ETAR and ETBR was determined using real-time polymerase chain reaction.
RESULTS: Treatment with Glytan reduced portal pressure (PP) and portal territory blood flow (PTBF) and increased both mean arterial pressure (MAP) and splanchnic vascular resistance (SVR). Especially at 4 wk, PP decreased by about 40%, while MAP increased by 13%, SVR increased by 12%, and PTBF decreased by about 21%. The effect of blood flow reduction was greatest in the mesentery (about 33%) at 4 wk. The mesenteric circulation ET-1 levels of BDL rats were lower and negatively correlated with PP at 4 wk. Glytan can increase mesenteric ET-1 content and inhibit ETBR, eNOS, GRK2, and β-arrestin 2 expression in the mesentery. Moreover, Glytan showed no effect on the expression of ETAR protein and mRNA.
CONCLUSION: The decreased PP and PTBF observed after Glytan treatment were related to increased mesenteric vasoconstriction and increased receptor sensitivity to vasoconstrictor.

Entities:  

Keywords:  Endothelin-1; Glytan; Hemodynamics; Mesentery; Portal hypertension; Receptor; Sensitivity

Mesh:

Substances:

Year:  2014        PMID: 25469036      PMCID: PMC4248211          DOI: 10.3748/wjg.v20.i44.16674

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Liver Int       Date:  2011-07-05       Impact factor: 5.828

2.  Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis.

Authors:  N Nagasue; D K Dhar; A Yamanoi; Y Emi; J Udagawa; A Yamamoto; M Tachibana; H Kubota; H Kohno; T Harada
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

Review 3.  Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

Authors:  Jaume Bosch; Juan G Abraldes; Mercedes Fernández; Juan Carlos García-Pagán
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

4.  Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice.

Authors:  Abraham Koshy; Andrea De Gottardi; Monika Ledermann; Hans Saegesser; Sidney G Shaw; Arthur Zimmermann; Jürg Reichen
Journal:  Liver Int       Date:  2005-10       Impact factor: 5.828

5.  Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.

Authors:  M Niederberger; P Ginés; P Y Martin; P Tsai; K Morris; I McMurtry; R W Schrier
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

6.  Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

7.  ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men.

Authors:  Felix Böhm; John Pernow; Jonas Lindström; Gunvor Ahlborg
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

8.  Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.

Authors:  Càndid Villanueva; Carles Aracil; Alan Colomo; Virginia Hernández-Gea; Josep M López-Balaguer; Cristina Alvarez-Urturi; Xavier Torras; Joaquim Balanzó; Carlos Guarner
Journal:  Gastroenterology       Date:  2009-04-01       Impact factor: 22.682

9.  Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt.

Authors:  Songling Liu; Richard T Premont; Christopher D Kontos; Jianhua Huang; Don C Rockey
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

10.  Cicletanine stimulates eNOS phosphorylation and NO production via Akt and MAP kinase/Erk signaling in sinusoidal endothelial cells.

Authors:  Songling Liu; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-05-02       Impact factor: 4.052

View more
  2 in total

1.  Gan Shen Fu Fang ameliorates liver fibrosis in vitro and in vivo by inhibiting the inflammatory response and extracellular signal-regulated kinase phosphorylation.

Authors:  Qing-Hong Du; Chu-Jun Zhang; Wei-Hong Li; Yan Mu; Ya Xu; Scott Lowe; Lin Han; Xue Yu; Shu-Yan Wang; Yu Li; Jian Li
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

2.  Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis.

Authors:  Xiaoli Du; Qianqian Tao; Hongxia Du; Zhenbang Zhao; Yu Dong; Shuang He; Rui Shao; Yule Wang; Wenrun Han; Xintong Wang; Yan Zhu
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.